SS Innovations Demonstrates Long-Distance Robotic Cardiac Surgery, Highlighting Potential to Extend Specialist Care

SS Innovations showcased its SSi Mantra system by performing remote robotic cardiac and other surgeries across thousands of miles, underscoring the potential of telesurgery to broaden access to specialized care while awaiting FDA clearance.

Houston Metrowire Staff
••Healthcare
SS Innovations Demonstrates Long-Distance Robotic Cardiac Surgery, Highlighting Potential to Extend Specialist Care

SS Innovations International (NASDAQ: SSII) has demonstrated the capabilities of its SSi Mantra surgical robotic system and SSi MantrAsana tele-surgeon console at two international medical conferences in October 2026, performing a robotic-assisted cardiac procedure on a patient located roughly 7,500 miles away. The announcement matters because it signals a step toward making specialized surgical expertise available beyond major medical centers, potentially improving access to care in underserved regions.

At the 40th European Association for Cardio-Thoracic Surgery annual meeting in Barcelona, the company’s chairman and CEO, Dr. Sudhir Srivastava, remotely performed an atrial septal defect procedure on a patient in Bengaluru, India. The distance between surgeon and patient was approximately 7,500 miles. In addition, four robotic telesurgeries were performed or broadcast during the inaugural Society of Robotic Surgery India conference, covering urological, colorectal, pediatric, and gynecological procedures.

The company reported that 205 telesurgeries have been performed with the SSi Mantra system as of October 23, 2026, including cardiac procedures. These demonstrations underscore the potential for remote robotic surgery to extend specialist expertise beyond major medical centers. However, widespread adoption will depend on clinical validation, connectivity, and regulatory requirements.

SS Innovations is pursuing U.S. Food and Drug Administration clearance for the SSi Mantra, with completion of the 510(k) review targeted for the first quarter of 2027, though the timeline remains subject to the FDA’s review. FDA clearance would be a critical milestone for the company, potentially opening the U.S. market and lending credibility to its technology.

The company showcased its platform in a series of remote operations during October medical conferences in Spain and India, including a robotic-assisted cardiac procedure performed by a surgeon approximately 7,500 miles from the patient (https://ibn.fm/EZFDT). For more details, readers can Read More. The latest news and updates relating to SSII are available in the company’s newsroom at https://ibn.fm/SSII. Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.ai/Disclaimer.

Blockchain Registration

QR Code for Blockchain Registration